Combination therapy in metastatic CRC

Adding cetuximab to the treatment regimen of patients with metastatic colorectal cancer (CRC) results in worse outcomes, a controlled trial has shown. Cetuximab has some efficacy against CRC; however, combination therapy with capecitabine, oxaliplatin, bevacizumab and cetuximab resulted in a median progression-free survival of 9.4 months, compared with 10.7 months for patients receiving the capecitabine, oxaliplatin and bevacizumab regimen (P = 0.01). Quality of life scores were also lower in the cetuximab group. Patients treated with cetuximab who had tumours bearing a mutated KRAS gene had significantly reduced progression-free survival compared to those without the mutation who were receiving cetuximab, or patients with the mutation not receiving cetuximab.

Tol J, Koopman M, Cats A et al. N Engl J Med 2009;360:563-72

Originally published in the March 2009 edition of MIMS Oncology & Palliative Care.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs